Sponsor content
73 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVTOZMA tocilizumab (rch) 162 mg/0.9 mL solution for injection pre-filled pen, AVTPen Autoinjector.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVTOZMA tocilizumab (rch) 200 mg/10 mL injection concentrated vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVTOZMA tocilizumab (rch) 80 mg/4 mL injection concentrated vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVTOZMA tocilizumab (rch) 400 mg/20 mL injection concentrated vial.
-
Australian Public Assessment Report (AusPAR)Eydenzelt (aflibercept) has been approved for the treatment in adults of visual impairment due to myopic choroidal neovascularisation.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for STOBOCLO denosumab (rch) 60 mg/mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OSENVELT denosumab (rch) 70 mg/mL solution for injection vial.
-
EYDENZELT aflibercept (rch) 40 mg/mL solution for intravitreal injection pre-filled syringe (431931)
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EYDENZELT aflibercept (rch) 40 mg/mL solution for intravitreal injection pre-filled syringe. -
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EYDENZELT aflibercept (rch) 40 mg/mL solution for intravitreal injection vial with needle.
-
Australian Public Assessment Report (AusPAR)OMLYCLO (omalizumab), a biosimilar to XOLAIR, is approved to treat allergic asthma, chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria.